Management of Bleeding Risk with Anticoagulant and Antiplatelet Therapy

Introduction to Bleeding Risk

The American Heart Association recommends that apixaban plus aspirin increases bleeding time by 1.96 times baseline, compared to 1.46 times with aspirin alone, demonstrating additive bleeding effects 1, 2
The American College of Cardiology suggests that combination oral anticoagulation plus aspirin increases bleeding risk approximately 2-fold compared to aspirin alone 3

The American Heart Association states that if aspirin is being used for primary prevention in a patient already on apixaban for atrial fibrillation or venous thromboembolism, it should generally be discontinued as the anticoagulant provides adequate stroke/thrombosis prevention 3
The American College of Chest Physicians recommends that if aspirin is indicated for secondary prevention after acute coronary syndrome or recent stenting, dual therapy may be justified for a limited duration, but triple therapy (adding Lexapro) requires heightened vigilance 4

The American Diabetes Association suggests using the lowest effective aspirin dose (75-81 mg daily) rather than higher doses, as doses above 75 mg increase bleeding risk without proportional benefit 3, 6
The American College of Gastroenterology recommends considering proton pump inhibitor therapy for gastrointestinal protection, particularly given the patient's age 5

The American Heart Association recommends discontinuing aspirin and relying on apixaban alone for thrombotic protection if the indication is atrial fibrillation or venous thromboembolism 3

The European Society of Anaesthesiology recommends baseline and periodic renal function assessment (creatinine clearance), as renal impairment increases apixaban levels and bleeding risk 7
The American College of Clinical Pharmacy suggests avoiding herbal supplements that affect bleeding (ginkgo, garlic, ginger, fish oil) or interact with apixaban (St. John's wort) 1, 2
The American Heart Association advises against assuming aspirin is necessary simply because it was previously prescribed—reassess the indication in light of current anticoagulation 3